Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARBLI vs INJECTAPAP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ARBLI (arbaclofen placarbil) is a prodrug of baclofen, a GABA-B receptor agonist. It acts presynaptically to inhibit excitatory neurotransmitter release and postsynaptically to reduce neuronal excitability, leading to muscle relaxation.
Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.
Spasticity due to multiple sclerosis,Spinal cord injury,Alcohol use disorder (off-label)
Management of mild to moderate pain,Reduction of fever
10 mg orally once daily.
1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.
Terminal elimination half-life of 26 hours (range 20-32 h), supporting once-daily dosing; prolonged in hepatic impairment.
2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Primarily hydrolyzed by esterases to baclofen; baclofen is minimally metabolized (mainly renal clearance of unchanged drug).
Primarily metabolized in the liver via conjugation (glucuronidation and sulfation) at therapeutic doses; a minor pathway via cytochrome P450 (CYP2E1, CYP1A2, and CYP3A4) produces a toxic metabolite (NAPQI) which is normally detoxified by glutathione.
Primarily biliary (>70%) and fecal elimination; renal excretion accounts for <5% of unchanged drug.
Renal: 2-5% unchanged; hepatic metabolism to glucuronide and sulfate conjugates, then renal excretion of metabolites. Biliary/fecal: minimal (<5%).
>99% bound to albumin and alpha-1-acid glycoprotein.
10-25% bound to albumin at therapeutic concentrations.
0.7 L/kg, indicating extensive tissue distribution.
0.8-1.0 L/kg; suggests distribution into total body water.
Oral: 70% (range 60-80%); IV: 100%.
IV: 100%; oral: 60-90% (first-pass metabolism); rectal: 30-50%.
e GFR ≥30 m L/min/1.73 m²: no adjustment. e GFR <30 m L/min/1.73 m²: use not recommended.
For GFR 30-60 m L/min: no adjustment; for GFR <30 m L/min: extend interval to every 8 hours; maximum 3 g per day.
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%, maximum 2 g per day; Child-Pugh C: contraindicated.
Not established for patients <18 years.
For weight ≥50 kg: 1 g every 6 hours; for weight 10-50 kg: 15 mg/kg every 6 hours; for weight <10 kg: 7.5 mg/kg every 6 hours; all intravenous.
No specific dose adjustment required; monitor renal function.
No specific dose adjustment required; consider decreased hepatic function and concomitant medications; maximum 3 g per day for patients with risk factors for hepatotoxicity.
Abrupt discontinuation may precipitate withdrawal reactions including seizures, hallucinations, and life-threatening hyperthermia (similar to baclofen withdrawal).
Acetaminophen has been associated with cases of acute liver failure, hepatotoxicity is primarily due to overdose. Risk is increased in patients with underlying liver disease, chronic alcohol use, and those taking multiple acetaminophen-containing products.
Risk of withdrawal symptoms with abrupt cessation,May cause sedation and dizziness,Use caution in renal impairment,May exacerbate psychiatric disorders,Avoid with alcohol or CNS depressants
Risk of hepatotoxicity, especially with doses exceeding 4 g/day or in patients with liver impairment,Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis,Hypersensitivity reactions,Use caution in patients with G6PD deficiency,Avoid use with other acetaminophen-containing products
Hypersensitivity to baclofen or any component of the formulation
Hypersensitivity to acetaminophen or any component of the formulation
Avoid alcohol. No specific food interactions reported, but take with or without food consistently to maintain stable drug levels.
No significant food interactions. However, concurrent ingestion of alcohol may increase risk of hepatotoxicity; avoid alcohol while on therapy.
ARBLI (arbaclofen) is not approved for use in pregnancy. No adequate and well-controlled studies in pregnant women. In animal studies, arbaclofen showed no teratogenic effects at doses up to 4 times the maximum recommended human dose based on body surface area. However, fetal toxicity (reduced fetal weight, delayed ossification) occurred at maternally toxic doses. Based on mechanism (GABAB agonist), potential risk cannot be excluded. First trimester: unknown risk; second/third trimester: possible risk of fetal harm from maternal muscle relaxation; third trimester: risk of neonatal withdrawal (hypotonia, respiratory depression) if used near term.
FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major malformations. Second and third trimesters: chronic high-dose use may be associated with increased risk of childhood asthma and attention-deficit/hyperactivity disorder (ADHD). Overdose poses risk of maternal and fetal hepatotoxicity.
No data on excretion in human milk. Arbaclofen is a small molecule (MW 215.68) and likely excreted into breast milk. M/P ratio unknown. Due to potential for serious adverse reactions (e.g., sedation, respiratory depression) in nursing infants, breastfeeding is not recommended during therapy.
Acetaminophen is excreted into breast milk in low concentrations (M/P ratio approximately 0.91-1.42). Reported infant dose is less than 2% of maternal weight-adjusted dose. Considered compatible with breastfeeding. Use lowest effective dose for shortest duration.
No specific dosing guidelines established for pregnancy due to lack of data. Pregnancy may alter pharmacokinetics (increased volume of distribution, renal clearance) potentially requiring dose adjustments; however, no recommendations can be made because drug is contraindicated in pregnancy.
No dose adjustment required for standard therapeutic use. Increased clearance in pregnancy may require shorter dosing intervals for pain control; consider maximum daily dose of 3 g/day instead of 4 g/day. Avoid prolonged use >48 hours without medical supervision.
ARBLI (arbaclofen) is a prodrug of baclofen used for spasticity. Titrate slowly to avoid CNS depression. Monitor renal function; dose adjustment required in Cr Cl <60 m L/min. Avoid abrupt discontinuation due to withdrawal symptoms. Use with caution in patients with history of substance abuse due to abuse potential.
Acetaminophen injection is indicated for treatment of acute pain and fever. Use with caution in hepatic impairment. Avoid in patients with severe active liver disease. Monitor liver function tests with prolonged use. Do not exceed maximum daily dose (4 g/day in adults). Use the smallest effective dose for the shortest duration.
Take exactly as prescribed; do not increase dose without consulting your doctor.,Do not stop taking abruptly; gradual dose reduction is necessary to prevent withdrawal symptoms (hallucinations, seizures, rapid heart rate).,Avoid driving or operating heavy machinery until you know how ARBLI affects you, as it may cause dizziness or drowsiness.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase sedation risk.,Inform your doctor if you have kidney problems, diabetes, or a history of substance abuse.,Store at room temperature away from moisture and heat.
Do not take more than the recommended dose. Overdose can cause severe liver damage.,Inform your healthcare provider if you have liver disease or drink alcohol regularly.,Check other medications for acetaminophen to avoid double dosing.,Seek immediate medical attention if you experience signs of liver injury (e.g., yellowing skin/eyes, dark urine, upper stomach pain).,This medication is administered by intravenous infusion; do not attempt self-administration.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARBLI vs INJECTAPAP, answered by our medical review team.
ARBLI is a Cephalosporin Antibiotic that works by ARBLI (arbaclofen placarbil) is a prodrug of baclofen, a GABA-B receptor agonist. It acts presynaptically to inhibit excitatory neurotransmitter release and postsynaptically to reduce neuronal excitability, leading to muscle relaxation.. INJECTAPAP is a Non-Opioid Analgesic that works by Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARBLI and INJECTAPAP depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARBLI is: 10 mg orally once daily.. The standard adult dose of INJECTAPAP is: 1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARBLI and INJECTAPAP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARBLI is classified as Category C. ARBLI (arbaclofen) is not approved for use in pregnancy. No adequate and well-controlled studies in pregnant women. In animal studies, arbaclofen showed no teratogenic effects at d. INJECTAPAP is classified as Category C. FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.